Why the study?
Alcohol misuse is common among individuals receiving opioid agonist maintenance treatment, prompting evaluation of screening and brief intervention in this population.
Does a single session screening and brief intervention (SBI) reduce alcohol misuse (AUDIT score) in participants on buprenorphine/naloxone-assisted opioid agonist maintenance treatment?
Does a single session screening and brief intervention (SBI) reduce alcohol misuse (AUDIT score) in participants on buprenorphine/naloxone-assisted opioid agonist maintenance treatment?
A single session of screening and brief intervention significantly reduces alcohol misuse and improves treatment adherence in patients on buprenorphine/naloxone maintenance.
Provides the first randomized evidence for brief alcohol interventions in buprenorphine-maintained patients;.
Alcohol misuse is common in persons on opioid agonist maintenance treatment (OAMT). We tested the efficacy of screening and brief intervention (SBI) for harmful/hazardous alcohol use in buprenorphine/naloxone (BNX)-assisted OAMT. It was a double-blind, parallel-group, randomized trial, where 150 participants with alcohol misuse (Alcohol Use Disorder Identification Test – AUDIT 8–19) on BNX were allocated equally to receive either a single session SBI or screening and brief advice (control). Participants were followed up at three months. The primary outcome was the change in AUDIT; other outcomes were risk transition, change in the frequency of heavy drinking, days of abstinence from alcohol, Gamma-glutamyl transferase (GGT) levels, non-prescription opioid use, and adherence to BNX. Follow-up data was gathered from 138 participants. SBI participants had a higher reduction in AUDIT scores at the follow-up (F = 129. 173, df = 1, p < .001, ηp2 =.469). A higher proportion of participants transitioned to a low-risk category in the SBI group. The SBI group showed a higher reduction in heavy drinking and days of alcohol abstinence. Although the proportion of persons with normal serum GGT increased in both groups, the difference was not significant at the follow-up. The SBI group performed better in non-prescription opioid use and BNX adherence.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: